[A19-20] Ocriplasmin (vitreomacular traction) - Addendum to Commission A18-68
|Commission:||Commission awarded on 2019-02-25 by the Federal Joint Committee (G-BA)|
|Current document:||Addendum to Commission A18-68 (German version) Further documents|
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|Contact address:||to the contact form|
Ocriplasmin (vitreomacular traction, including when associated with macular hole) - Benefit assessment according to §35a Social Code Book V (reassessment after expiry of the decision)
Status: Commission completed
|2019-04-04||Addendum to Commission A18-68 (German version)||136 kB|
Federal Joint Committee (G-BA)
2019-04-04 A G-BA decision was published.